Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting.
Aluwini SS, Mehra N, Lolkema MP, Oprea-Lager DE, Yakar D, Stoevelaar H, van der Poel H; Dutch Oligometastatic Prostate Cancer Working Group; Busstra M, de Jong IJ, de Reijke T, de Vries K, Heijmink S, Jenster G, Klaver S, Kneppers J, Lavalaye J, Leyten G, Moonen L, Nagaraj J, Noordzij W, Osanto S, Oving I, Schaake E, Scheenen T, Schoots I, Sedelaar M, Somford D, van den Berkmortel F, van der Hulle T, van der Voort van Zyp J, van Leeuwen P, van Moorselaar J, van Oort I, Vogel W, Westgeest H. Aluwini SS, et al. Eur Urol Oncol. 2020 Apr;3(2):231-238. doi: 10.1016/j.euo.2019.07.010. Epub 2019 Aug 8. Eur Urol Oncol. 2020. PMID: 31401014
Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, Alemayehu WG, Heemsbergen W, Heijmen B, Incrocci L. Aluwini S, et al. Lancet Oncol. 2016 Apr;17(4):464-474. doi: 10.1016/S1470-2045(15)00567-7. Epub 2016 Mar 9. Lancet Oncol. 2016. PMID: 26968359 Clinical Trial.
Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L, Wortel RC, Alemayehu WG, Aluwini S, Schimmel E, Krol S, van der Toorn PP, Jager H, Heemsbergen W, Heijmen B, Pos F. Incrocci L, et al. Lancet Oncol. 2016 Aug;17(8):1061-1069. doi: 10.1016/S1470-2045(16)30070-5. Epub 2016 Jun 20. Lancet Oncol. 2016. PMID: 27339116 Clinical Trial.
Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol.
Staal FHE, Janssen J, Brouwer CL, Langendijk JA, Ng Wei Siang K, Schuit E, de Jong IJ, Verzijlbergen JF, Smeenk RJ, Aluwini S. Staal FHE, et al. BMC Cancer. 2022 Apr 15;22(1):416. doi: 10.1186/s12885-022-09493-5. BMC Cancer. 2022. PMID: 35428210 Free PMC article.
M1a prostate cancer: Results of a Dutch multidisciplinary consensus meeting.
Aluwini S, Oprea-Lager DE, de Barros H, Mehra N, Stoevelaar H, Yakar D, van der Poel H; Dutch M1a Prostate Cancer Working Group. Aluwini S, et al. BJUI Compass. 2021 Feb 3;2(3):159-168. doi: 10.1002/bco2.73. eCollection 2021 May. BJUI Compass. 2021. PMID: 35475128 Free PMC article.
Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting.
Mehra N, Kloots I, Vlaming M, Aluwini S, Dewulf E, Oprea-Lager DE, van der Poel H, Stoevelaar H, Yakar D, Bangma CH, Bekers E, van den Bergh R, Bergman AM, van den Berkmortel F, Boudewijns S, Dinjens WNM, Fütterer J, van der Hulle T, Jenster G, Kroeze LI, van Kruchten M, van Leenders G, van Leeuwen PJ, de Leng WWJ, van Moorselaar RJA, Noordzij W, Oldenburg RA, van Oort IM, Oving I, Schalken JA, Schoots IG, Schuuring E, Smeenk RJ, Vanneste BGL, Vegt E, Vis AN, de Vries K, Willemse PM, Wondergem M, Ausems M. Mehra N, et al. Eur Urol Open Sci. 2023 Jan 25;49:23-31. doi: 10.1016/j.euros.2022.11.011. eCollection 2023 Mar. Eur Urol Open Sci. 2023. PMID: 36874601 Free PMC article.
Skeletal 18F-PSMA-1007 uptake in prostate cancer patients.
Janssen J, Noordzij W, Velleman T, de Jong IJ, Langendijk JA, Verzijlbergen JF, Stormezand GN, Aluwini S. Janssen J, et al. Ther Adv Med Oncol. 2023 Jun 29;15:17588359231179311. doi: 10.1177/17588359231179311. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37441326 Free PMC article.
Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Based Clinical Target Volume Delineation Guideline for Postprostatectomy Salvage Radiation Therapy: The PERYTON Guideline.
Staal FHE, Janssen J, Oprea-Lager DE, Engelen AM, van Limbergen EJ, Smeenk RJ, de Jong MAA, Budiharto TCG, Jacobs I, Haverkort DMAD, Brouwer CL, Ng Wei Siang K, Langendijk JA, Verzijlbergen JF, de Jong IJ, Noordzij W, Aluwini S. Staal FHE, et al. Int J Radiat Oncol Biol Phys. 2024 Mar 1;118(3):688-696. doi: 10.1016/j.ijrobp.2023.09.016. Epub 2023 Sep 18. Int J Radiat Oncol Biol Phys. 2024. PMID: 37729971
40 results